Fig. (3) The reduction in prescriptions, described as the decline in
Defined Daily Dose (DDD) for every 1.000 of the physicians own
patients for N05CF (cyclopyrrolones, e.g. zopiclon) for the last
quarter of 2006 compared to the average DDD for the four quarters
of 2003.